[Statins in COPD--theoretical reflections].
Systemic inflammation is thought to play a role in the pathogenesis and extrapulmonary manifestations (including cardiovascular disease) of COPD. In addition to cholesterol-lowering properties, statins have anti-inflammatory properties, which may also have positive effects on cardiovascular morbidity and mortality. Therefore, it can be hypothesized that statins may play a role in prevention of COPD progression and the development of extrapulmonary manifestations of COPD. Statins may have positive effects on lung function decline, exacerbation frequency, exercise tolerance and mortality in COPD patients, but the evidence is weak. It is unclear whether these findings are the result of anti-inflammatory properties and/or of cholesterol-lowering properties in patients with (unrecognized) cardiovascular disease.
Universitair Medisch Centrum St Radboud, Afd. Longziekten, Nijmegen, the Netherlands. j.hannink@elg.umcn.nl
Jorien D C
JD
Hannink
Yvonne F
YF
Heijdra
D000893:Anti-Inflammatory Agents / Q000627:therapeutic use*; D002318:Cardiovascular Diseases / Q000401:mortality / Q000517:prevention & control*; D018450:Disease Progression; D006801:Humans; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors / Q000627:therapeutic use*; D029424:Pulmonary Disease, Chronic Obstructive / Q000150:complications / Q000188:drug therapy* / Q000401:mortality
D000893:Anti-Inflammatory Agents; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors